INSPHERO AG

Their core work

InSphero is a Swiss biotech SME specializing in 3D microtissue and organ-on-chip technologies for drug testing, toxicology, and disease modeling. They produce standardized 3D cell culture platforms (spheroids and organoids) that replace or reduce animal testing by providing physiologically relevant human tissue models. Their core commercial offering enables pharmaceutical and chemical companies to screen compounds for safety and efficacy using realistic human tissue responses rather than traditional 2D cell cultures or animal models.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), InSphero contributed their 3D tissue platforms to diverse applications — from cell migration assays (MATRIXASSAY) to diabetes-related organoid work (LSFM4LIFE) and foundational systems toxicology (EU-ToxRisk). From 2019 onward, their focus sharpened significantly toward regulatory-grade toxicology: next-generation risk assessment, quantitative adverse outcome pathway (AOP) networks, and gaining regulatory acceptance for non-animal testing. This shift reflects a maturation from broad platform demonstration to positioning their technology as a validated regulatory tool.

InSphero is moving from being a technology provider toward becoming a regulatory-accepted alternative to animal testing, which positions them for growing demand as EU chemicals regulation tightens.

How they like to work

InSphero operates predominantly as a specialist participant (5 of 7 projects), contributing their proprietary 3D tissue technology to large research consortia. They coordinated only once (ARON, an SME Phase 1 feasibility study), suggesting they prefer to embed their commercial platform into larger collaborative efforts rather than lead them. With 153 unique partners across 21 countries, they are well-connected and comfortable working across large, multi-national consortia.

InSphero has built a broad European network of 153 unique consortium partners across 21 countries, largely through participation in major flagship health and toxicology programs like EU-ToxRisk and RISK-HUNT3R. Their network spans academic institutions, regulatory bodies, and pharma/chemical industry players involved in safety assessment.

What sets them apart

InSphero occupies a rare niche as a commercial SME that produces standardized, assay-ready 3D human microtissues at scale — bridging the gap between academic organoid research and industrial drug/chemical safety testing. Unlike academic partners who develop bespoke models, InSphero delivers reproducible, off-the-shelf tissue platforms that can be integrated into high-throughput screening workflows. Their sustained involvement in both EU-ToxRisk and its successor RISK-HUNT3R shows they are a trusted technology provider in Europe's push to replace animal testing.

Highlights from their portfolio

• PATROLS
  Largest single EC contribution (EUR 481,961) — used InSphero's tissue models to develop realistic nanomaterial hazard assessment tools.
• EU-ToxRisk
  Major European flagship program in mechanism-based toxicology, spanning 2016–2021, placing InSphero at the center of Europe's non-animal testing strategy.
• ARON
  InSphero's only coordinated project — an SME Phase 1 exploring their 'Assay-Ready Organ Network' concept for multi-organ testing.